Pipeline

Doctor discussing information with an elderly patient in a bright, modern medical office.

We are dedicated to reimagining how cancer is treated and focused on developing first-in-class solutions that support patient journeys.

We have a proven ability to advance innovative and differentiated cancer programs and a strong record of adhering to scientific excellence, following promising clinical data and real-world utilization.

Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor.

As our leading core value states, we are fueled by our passion for patients—this passion drives us in our pursuit to execute on our mission and continues to drive our innovation to realize the full potential of our pipeline.

Doctor discussing medical information with a patient, holding a tablet and gesturing.

Investigating Revumenib for NPM1m Acute Myeloid Leukemia

In November 2024, the Company announced positive topline data from the relapsed or refractory (R/R) mutant NPM1 (NPM1m) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a pivotal trial designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of orally administered revumenib. The Phase 2 pivotal portion of AUGMENT-101 enrolled R/R patients with R/R NPM1m AML. The primary endpoint for each of the cohorts is efficacy as measured by complete remission rate (CR + CRh) per protocol, with secondary endpoints including duration of response and overall survival (OS). Syndax anticipates submitting a supplemental NDA (sNDA) based on this positive data from the pivotal AUGMENT-101 trial of revumenib in adults and pediatric patients with NPM1m AML in the first half of 2025. You can learn more HERE.